Search

Displaying results 2281 - 2290 of 5419 in total
  1. Drug

    Alectinib

    go.drugbank.com/drugs/DB11363
    ApprovedInvestigational

    Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance

  2. Drug

    Dactylis glomerata pollen

    go.drugbank.com/drugs/DB10379
    Approved

    Dactylis glomerata pollen is the pollen of the Dactylis glomerata plant. Dactylis glomerata pollen is mainly used in allergenic testing.

  3. Drug

    Lolium perenne pollen

    go.drugbank.com/drugs/DB10389
    Approved

    Lolium perenne pollen is the pollen of the Lolium perenne plant. Lolium perenne pollen is mainly used in allergenic testing.

  4. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

  5. Drug

    Anthoxanthum odoratum pollen

    go.drugbank.com/drugs/DB10404
    Approved

    Anthoxanthum odoratum pollen is the pollen of the Anthoxanthum odoratum plant. Anthoxanthum odoratum pollen is mainly used in allergenic testing.

  6. Drug

    Lonidamine

    go.drugbank.com/drugs/DB06266
    Investigational

    In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs. … Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK).

  7. Drug

    Prednicarbate

    go.drugbank.com/drugs/DB01130
    Approved

    It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.

  8. Drug

    Pemivibart

    go.drugbank.com/drugs/DB18720
    Investigational

    [L50326] It received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis (PrEP) of COVID-19 in certain high-risk patient populations.

  9. Drug

    Teriflunomide

    go.drugbank.com/drugs/DB08880
    ApprovedInvestigational

    Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.

  10. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.